secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2024-07-19T23:59:59+00:00
Accession:  0001193125-24-181329
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Soleno grants performance-based RSUs to executives tied to DCCR NDA milestones
------------------------------------------------------------------------------

- CEO Anish Bhatnagar receives 850,000 performance-based RSUs; CFO James Mackaness 100,000; SVP Patricia Hirano 85,000.
- Vesting: 25% on Aug 1, 2024; 25% on FDA acceptance of DCCR NDA for Prader-Willi syndrome; 50% on FDA approval.
- Board increased 2014 Equity Incentive Plan by 2,000,000 shares, approved by 68.6% of votes at June 2024 annual meeting.
- Grants aim to bring key employee equity ownership in line with peer group median.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312524181329/0001193125-24-181329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312524181329/d839231d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-181329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer